Anthera Pharma (ANTH) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
May 9, 2016 8:38 AM EDTSOLUTION clinical study of Sollpura expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical OfficerEnrollment of BRIGHT-SC Phase 2 clinical study in IgA Nephropathy completedBulk manufacturing campaign for blisibimod completed for CHABLIS-7.5
HAYWARD, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the first quarter ended March 31, 2016.
Recent Developments and Business Highlights:
Sollpura (liprotamase)... More
